Syngene International Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kstbucx1vb0vv82kh0oh5rf1.pdf

Key Takeaways


Demand Recovery & Market Dynamics

Hunt: "Growth in the quarter suggests that market dynamics, particularly in US biotech, are stabilising, albeit later than expected."

Divisional Performance

Hunt: "Syngene's third quarter performance saw a return to growth across all business divisions that sets us up well for the next quarter."

Margins & Cost Structure

Jain: "Reported profit after tax (before exceptional items) for the quarter grew by 14% supported by operating EBITDA margins that came in at 30.1%, up from 27.1% in the previous year."

Exceptional Items & Accounting Changes


Operational Milestones


Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenue growthSingle-digit growthFY25 close
Full-year PATFlat PATFY25 close
EBITDA guidanceUnchanged from prior guidanceFY25
Q4 momentumGrowth momentum to continueQ4 FY25
Discovery Services contract contributionPilot-to-contract conversions to contribute to growthInto next year (FY26)

Key Metrics

MetricQ3 FY25
Revenue from operations₹944 crores, +11% YoY and +6% QoQ
Reported revenue₹962 crores, +9% YoY
EBITDA from operations₹284 crores, +22.5% YoY
EBITDA from operations margin30.1%, up 293 bps YoY from 27.1%
Reported EBITDA₹302 crores, +16% YoY
Reported EBITDA margin31.4%, up from 29.5% YoY
PAT before exceptional items₹131 crores, +14% YoY
PAT margin (before exceptional items)13.6%, up 65 bps YoY from 13.0%
PAT after exceptional items₹131 crores, +18% YoY
Full-year revenue growth guidanceSingle-digit growth, EBITDA guidance unchanged
Full-year PAT guidanceFlat, versus prior year
Staff costs as % of revenue from operations29.3%, up 82 bps YoY from 28.4%
Material costs as % of revenue from operations25.2%, improved 266 bps YoY from 27.8%
Foreign exchange gain, net₹1.7 crore gain, versus ₹12.4 crore loss in Q3 FY24
Cash and cash equivalents₹183 crore, versus ₹85.7 crore as of March 2024